Pd-1

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 27.10.2026

Dieser Artikel auf Deutsch

Synonym(s)

Programmed Death-1

Definition
This section has been translated automatically.

The PD-1 protein (PD-1 = acronym for "Programmed Death-1") is a membrane receptor (PD-1 receptor) consisting of 268 amino acids. Like CTL-4, PD-1 is a member of the extended CD28 / CTLA-4 family. Its molecular structure comprises an extracellular IgV domain, followed by a transmembrane region and an intracellular domain.

The gene coding for PD-1 is the PDCD1 gene (PDCD1 stands for: Programmed Cell Death 1), which is located on chromosome 2q37.3.

General information
This section has been translated automatically.

Tumor cells often mask themselves to evade elimination, for example, by expressing the programmed death ligands PD-L1 and PD-L2 on their surface. When the PD-1 receptor protein binds to its ligand on activated T cells, it suppresses the antitumor immune response. The CD28/CTLA-4 protein family thus acts as a T-cell regulator and inhibits T-cell activation following antigen stimulation. Compared to CTLA-4, the PD-1 receptor exhibits greater and broader selectivity for immunosuppressive signals triggered directly by tumor cells or tumor stromal cells. It was therefore expected that modulation or antagonism of this regulatory mechanism (see below PD-1 antibodies) would exhibit greater antitumor efficacy than the antagonism of the CTL-4 receptor protein (see below: Ipilimumab). Substances that follow this approach are also referred to as “checkpoint modifiers” or “checkpoint inhibitors.”  

General therapy
This section has been translated automatically.

A humanized monoclonal antibody against the surface protein PD-1 is pembrolizumab, which is currently being used successfully in the KEYNOTE-002 study in ipilimumab-resistant metastatic malignant melanoma.

Literature
This section has been translated automatically.

  1. Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454
  2. Blank C et al (2004) PD-L1 / B7H-1 inhibits the effector phase of tumor rejection by T-cell receptor (TCR) transgenic CD8 + T-cells. Cancer Res 64: 1140-1145
  3. Ribas A et al(2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractorymelanoma
    (KEYNOTE-002): a randomised, controlled, phase 2 trial.Lancet Oncol.16:908-918.

Authors

Last updated on: 27.10.2026